Ecolab Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; fourth-quarter figures are included. Ecolab provides water, hygiene, infection-prevention and related products and services globally. The 2021 acquisition of Purolite expanded its Life Sciences business; the 2020 ChampionX separation is reported as discontinued operations.
Financial performance
- Revenue: FY 2022 net sales were $14.19 billion, up 11% reported and 16% at fixed currency rates. Acquisition-adjusted fixed-currency sales grew 13%, reflecting 10% pricing and 2% volume growth. Fourth-quarter sales were $3.67 billion versus $3.36 billion a year earlier.
- Profit and EPS: GAAP operating income was $1.56 billion, down 2%; operating margin was 11.0%, versus 12.6%. Net income attributable to Ecolab was $1.09 billion, down 3%, and diluted EPS was $3.81, down 3%. Adjusted diluted EPS, a non-GAAP measure, was $4.49, down 4%. Fourth-quarter net income was $264 million and diluted EPS was $0.93, compared with $301 million and $1.04 in Q4 2021.
- Margins and costs: Reported gross margin fell to 37.8% from 40.2%; adjusted gross margin was 38.2% versus 40.9%. Pricing helped offset substantial delivered-product cost inflation, but inflation, unfavorable mix and business investment pressured margins. SG&A was 25.8% of sales, down from 26.8%.
- Cash flow and investment: Cash from continuing operating activities was $1.79 billion, down from $2.06 billion. Management attributed the decline primarily to a $277 million increase in working capital, including higher receivables and inventory. Capital expenditures were $713 million. Dividends paid were $603 million and share repurchases were $518 million.
- Debt and liquidity: Total debt was $8.58 billion, versus $8.76 billion, and cash was $599 million, versus $360 million. Net debt to EBITDA was 3.2x, compared with 3.4x. Ecolab had a $2.0 billion revolving credit facility maturing in April 2026, with no borrowings under it at year-end; no commercial paper was outstanding. The company reported compliance with debt covenants.
- Other balance-sheet measures: Total assets were $21.46 billion and total liabilities $14.21 billion. Goodwill was $8.01 billion. The reported GAAP tax rate was 17.5%, versus 19.1% in 2021.
Changes versus the prior year
- Reported sales growth accelerated to 11% from 8% in 2021, led by pricing; foreign-currency translation reduced 2022 reported growth by approximately 4 percentage points.
- Despite sales growth, higher input costs and investment weighed on profitability: reported operating income declined 2%, adjusted operating income declined 1%, and adjusted gross margin fell 2.7 percentage points.
- Operating cash flow declined $274 million, primarily due to working-capital investment. Cash increased year over year, while total debt decreased modestly.
- Global Institutional & Specialty and Other delivered strong growth. Global Industrial sales rose 14% at fixed currency, but its operating income declined 1%. Healthcare & Life Sciences sales rose 37% at fixed currency largely due to Purolite; excluding acquisition effects, sales were flat and adjusted operating income declined.
Outlook, risks and unusual items
- Management expected high delivered-product costs, unfavorable currency translation and interest-rate impacts to persist into 2023, with a more challenging macroeconomic environment, particularly in Europe. The filing does not provide a specific 2023 revenue or EPS forecast.
- In February 2023, Ecolab expanded its restructuring program beyond Europe. It then expected total pre-tax charges of $195 million and annual savings of $175 million by 2024, with actions expected to be completed by 2024. These are post-year-end expectations.
- 2022 special charges totaled $261 million, including $67 million of Europe restructuring charges, $39.5 million of Purolite acquisition and integration costs, $13.1 million related to Russia and Ukraine, and $50.6 million of U.S. pension settlement expense. Reported results and non-GAAP adjusted results differ; adjusted measures exclude specified charges and, where applicable, acquisition and discrete-tax effects.
- Ecolab limited Russian operations to activities it considered essential to life. Russia and Ukraine asset recoverability charges were recorded; the company said its Russian operations represented about 1% of sales in 2021 and 2022.
- Key exposures include inflation and supply constraints, foreign exchange and interest rates, economic weakness in customer markets, geopolitical developments, regulatory and environmental requirements, cyber risk, and acquisition integration. Approximately 47% of 2022 sales originated outside the U.S.
- Contingencies: Nalco is a defendant in numerous lawsuits arising from the 2019 TPC Group plant explosion; more than 5,000 plaintiffs had asserted claims. Ecolab said it could not estimate a loss or range at that stage, believed the claims were without merit, and expected potential loss to be covered by insurance subject to deductibles. Environmental remediation accruals were approximately $9.6 million; Ecolab stated it did not expect the ultimate resolution of environmental matters to be material.
- Audit and controls: PwC issued an unqualified opinion on the financial statements and internal control. Goodwill impairment for the Downstream reporting unit was identified as a critical audit matter because of management judgment, including the discount-rate assumption; no goodwill impairment was recorded in 2022.
Important facts for investors to verify
- Whether pricing continues to offset input-cost inflation and whether margins recover, especially in Global Industrial and Healthcare & Life Sciences.
- Whether working capital converts back into cash and operating cash flow supports capital spending, dividends, repurchases and debt service.
- Progress, total costs and realized savings from the expanded restructuring plan; compare the February 2023 targets with subsequent disclosures.
- Developments in the TPC litigation, insurance coverage and any change in the company’s ability to estimate potential exposure.
- Debt maturity and interest-rate exposure, credit outlooks, and progress integrating Purolite and sustaining its performance.
- Reconcile GAAP results with the company’s non-GAAP measures and assess the recurring nature of charges excluded from adjusted results.